Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
H
061250
vs
K
KOSPI 200
Over the past 12 months, Hwail Pharm Co Ltd has underperformed KOSPI 200, delivering a return of -45% compared to KOSPI 200's +119% growth.
Stocks Performance
061250 vs KOSPI 200
Performance Gap
061250 vs KOSPI 200
Performance By Year
061250 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hwail Pharm Co Ltd
Glance View
Hwail Pharm is a South Korean pharmaceutical company that makes and sells finished medicines and related health products. Its core business is turning drug formulas into packaged products that can be prescribed by doctors or sold through pharmacies and other healthcare channels. In plain terms, it sits on the manufacturing side of the drug supply chain, where quality, regulatory approval, and reliable production matter most. The company sells to hospitals, clinics, pharmacies, and wholesalers rather than to individual patients. It makes money by selling its own branded or generic medicines, and in some cases by producing products for other healthcare customers or distributors. That means its revenue depends on getting products approved, manufacturing them consistently, and keeping those products in the channels that doctors and pharmacists use. What makes the business model different is that drug makers like Hwail Pharm do not win just by advertising. They have to develop formulations, meet strict safety and quality rules, and maintain trust with medical buyers. In that sense, the company is an industrial supplier for healthcare: it converts regulated chemistry and manufacturing know-how into products that patients actually use.